CN115074326A - Culture method for in-vitro amplification of NK cells by combining CD16 antibody with cytokine - Google Patents
Culture method for in-vitro amplification of NK cells by combining CD16 antibody with cytokine Download PDFInfo
- Publication number
- CN115074326A CN115074326A CN202210794041.7A CN202210794041A CN115074326A CN 115074326 A CN115074326 A CN 115074326A CN 202210794041 A CN202210794041 A CN 202210794041A CN 115074326 A CN115074326 A CN 115074326A
- Authority
- CN
- China
- Prior art keywords
- cells
- culture
- antibody
- vitro
- pbs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 43
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 title claims abstract description 30
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 title claims abstract description 30
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 title claims abstract description 30
- 238000000338 in vitro Methods 0.000 title claims abstract description 17
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 14
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 14
- 238000012136 culture method Methods 0.000 title claims abstract description 12
- 230000003321 amplification Effects 0.000 title abstract description 9
- 238000003199 nucleic acid amplification method Methods 0.000 title abstract description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 15
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 14
- 239000001963 growth medium Substances 0.000 claims abstract description 13
- 238000004113 cell culture Methods 0.000 claims abstract description 10
- 108010056030 retronectin Proteins 0.000 claims abstract description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 239000011886 peripheral blood Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 6
- 239000001569 carbon dioxide Substances 0.000 claims description 6
- 239000006285 cell suspension Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 210000005087 mononuclear cell Anatomy 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 230000001133 acceleration Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 230000007480 spreading Effects 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 210000002993 trophoblast Anatomy 0.000 abstract description 5
- 239000011324 bead Substances 0.000 abstract description 4
- 230000020411 cell activation Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract description 3
- 230000002147 killing effect Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 239000002609 medium Substances 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the field of methods for amplifying NK cells in vitro, in particular to a culture method for amplifying NK cells in vitro by combining CD16 antibodies with cytokines. The invention inoculates peripheral blood mononuclear cells into pre-coated RetroNectin and mouse anti-human CD16 cell culture flasks, and adds a culture medium containing IL-2, IL-15, IL-21 and autologous plasma. The anti-CD 16 antibody is combined with the CD16 site of NK cell surface cells to enhance the stimulation of IL-15 and IL-2 to NK cells and the killing effect of ADCC to tumor cells, so that the NK cells are induced to be activated, and the NK cells with higher amplification efficiency and purity are obtained. The technology does not use magnetic beads to sort cells, does not use a trophoblast cell activation method, and has the advantages of simple operation, quick response, low preparation cost and high safety. Can efficiently amplify NK cells, and the cells are amplified by 148 times within 14 days. The NK cells have high purity and high clinical value.
Description
Technical Field
The invention relates to the field of methods for amplifying NK cells in vitro, in particular to a culture method for amplifying NK cells in vitro by combining CD16 antibodies with cytokines.
Background
In the existing technology for amplifying NK cells in vitro, a cell culture method adopts Herceptin, Herceptin and PHA, RetroNectin + Merocin + mouse anti-human CD161 antibody clad plate, hyaluronic acid + CD16+
RetroNectin et al, as well as classical methods using trophoblasts. The method is easy to introduce safety problems in the operation process (for example, the introduction of various exogenous factors or reagents can increase the difficulty of cell quality control, thereby increasing the risk of clinical application), and has the problems of unstable process and higher cost due to complex operation.
Disclosure of Invention
In order to solve the problems in the prior art, a culture method for in vitro expansion of NK cells by combining a CD16 antibody and a cytokine is provided. The invention inoculates peripheral blood mononuclear cells into pre-coated RetroNectin and mouse anti-human CD16 cell culture flasks, and adds a culture medium containing IL-2, IL-15, IL-21 and autologous plasma. The method does not use magnetic beads to sort cells, does not use a trophoblast cell activation method, and has the advantages of simple operation, quick response, low preparation cost and high safety. Can efficiently amplify NK cells, and the cells are amplified by 148 times within 14 days.
The invention provides a culture method for in vitro amplification of NK cells by combining CD16 antibody with cytokines, which comprises the following steps:
s1, separating mononuclear cells from peripheral blood;
s2, inoculating peripheral blood mononuclear cells into a precoated RetroNectin and mouse anti-human CD16 cell culture bottle, and adding a culture medium containing IL-2, IL-15, IL-21 and autologous plasma;
s3, continuously culturing for 14-17 days to obtain high-purity high-activity NK cells.
Preferably, the coating solution is prepared before the culture.
Preferably, the coating solution comprises 10ml PBS, 35ug Retrocectin and 35ug CD16, and is prepared by mixing.
Preferably, the specific steps comprise:
A. coating: adding the coating solution into a culture bottle, uniformly spreading and flatly placing, and keeping out of the sun overnight at the temperature of 4 ℃;
B. blood collection: collecting 15ml of peripheral blood, and adding the peripheral blood into a first centrifugal tube for later use;
C. separating lymphocyte separating medium: adding PBS with the same volume as the PBS to 30ml into a centrifuge tube, uniformly mixing, transferring to a centrifuge tube II added with 15ml of lymph separation liquid in advance, centrifuging at 1800rpm/800g at room temperature for 20min, and setting the speed of acceleration and deceleration as 0;
D. washing PBMC: sucking out the white PBMC layer after centrifugation by using a suction tube, adding 18-22ml of PBS into the centrifuge tube III for cleaning, centrifuging for 6min at 2000rpm, and discarding the supernatant; washing with 20ml PBS again, centrifuging at 1800rpm for 6min, and discarding the supernatant; resuspending, mixing and sampling by using a culture medium, counting by adopting typan blue staining, centrifuging for 6min at 1800rpm, and discarding the supernatant;
E. preparing a cell suspension: suspending the cells with 40ml of culture medium, precipitating and mixing;
F. inoculating cells: adding 40ml of the cell suspension into a culture bottle, adding IL-15 with the final concentration of 30ng/ml, IL-21 with the final concentration of 100ng/ml, autologous plasma with the final concentration of 5% and IL-2 with the final concentration of 6000U/ml, and culturing the inoculated culture bottle in a carbon dioxide incubator;
G. flasks were grown at 4, 6, 8, 11 and 14 days during which time they were examined and cells recovered on day 17.
Preferably, the culture conditions of the carbon dioxide incubator are as follows: at a temperature of 37 ℃ and CO 2 The concentration was 5%.
Compared with the prior art, the invention has the following beneficial technical effects:
the invention inoculates peripheral blood mononuclear cells into cell culture flasks precoated with RetroNectin and mouse anti-human CD16, and adds a culture medium containing IL-2, IL-15, IL-21 and autologous plasma. The anti-CD 16 antibody is combined with a CD16 site of an NK cell epitope to enhance the stimulation of IL-15 and IL-2 to NK cells and the killing effect of ADCC to tumor cells, so that the NK cells are induced to be activated, and the NK cells with higher amplification efficiency and purity are obtained. The technology does not use magnetic beads to sort cells, does not use a trophoblast cell activation method, and has the advantages of simple operation, quick response, low preparation cost and high safety. Can efficiently amplify NK cells, and the cells are amplified by 148 times within 14 days. The NK cells have high purity and high clinical value.
Drawings
FIG. 1 is a schematic flow chart of a method according to an embodiment of the present invention;
FIG. 2 is a schematic diagram of NK cell expansion within 14 days;
FIG. 3 is a diagram showing the results of flow assay of NK cells.
Detailed Description
Example one
The invention provides a culture method for in vitro amplification of NK cells by combining CD16 antibody and cytokine, which comprises the following steps:
s1, separating mononuclear cells from peripheral blood;
s2, inoculating the peripheral blood mononuclear cells into a precoated RetroNectin and mouse anti-human CD16 cell culture bottle, and adding a culture medium containing IL-2, IL-15, IL-21 and autologous plasma;
s3, continuously culturing for 14-17 days to obtain high-purity high-activity NK cells.
Example two
The invention provides a culture method for in vitro amplification of NK cells by combining CD16 antibodies and cytokines, which comprises the following steps:
s1, separating mononuclear cells from peripheral blood;
s2, inoculating peripheral blood mononuclear cells into a precoated RetroNectin and mouse anti-human CD16 cell culture bottle, and adding a culture medium containing IL-2, IL-15, IL-21 and autologous plasma;
s3, continuously culturing for 14-17 days to obtain high-purity high-activity NK cells.
Furthermore, a coating solution is prepared before culturing.
Further, the coating solution was prepared by mixing 10ml of PBS, 35ug of Retrocin and 35ug of CD 16.
EXAMPLE III
As shown in figure 1, the culture method for the in vitro amplification of NK cells by the CD16 antibody and the cytokine comprises the following steps:
A. coating: adding the coating solution into a T75 culture flask, uniformly spreading, and keeping flat at 4 ℃ in a dark overnight;
B. blood collection: collecting 15ml of peripheral blood, and adding the peripheral blood into a 50ml centrifuge tube I for later use;
C. separating lymphocyte separating medium: adding PBS with the same volume as the PBS to 30ml into a centrifuge tube, uniformly mixing, transferring to a centrifuge tube II added with 15ml of lymph separation liquid in advance, centrifuging at 1800rpm/800g at room temperature for 20min, and setting the speed of acceleration and deceleration as 0;
D. washing PBMC: sucking out the white PBMC layer after centrifugation by using a Pasteur pipette, adding 18-22ml of PBS into a centrifuge tube III for washing, centrifuging for 6min at 2000rpm, and discarding the supernatant; washing with 20ml PBS again, centrifuging at 1800rpm for 6min, and discarding the supernatant; resuspending in 20ml culture medium, mixing, sampling, counting with typan blue stain, centrifuging at 1800rpm for 6min, and discarding the supernatant;
E. preparing a cell suspension: resuspending cells with 40ml GT-T551H3 medium, precipitating, and mixing;
F. inoculating cells: adding 40ml of the cell suspension into a culture bottle, adding IL-15 with the final concentration of 30ng/ml, IL-21 with the final concentration of 100ng/ml, autologous plasma with the final concentration of 5% and IL-2 with the final concentration of 6000U/ml, and culturing the inoculated culture bottle in a carbon dioxide incubator; the culture conditions of the carbon dioxide incubator are as follows: at a temperature of 37 ℃ and CO 2 The concentration is 5%;
G. culturing for 4, 6, 8, 11 and 14 days in separate flasks, detecting during the culture period, and recovering cells on day 17;
H. and (3) detecting the surface markers CD3, CD56, CD16 and CD45 of the NK cells by adopting a flow detection method. As a result, as shown in FIG. 3, it was found that CD45 was 63.47% and CD3-CD56+ was 62.63% after 14 days of cell culture.
Peripheral blood mononuclear cells are inoculated into a precoated RetroNectin and mouse anti-human CD16 cell culture flask, and a culture medium containing IL-2, IL-15, IL-21 and autologous plasma is added. The anti-CD 16 antibody is combined with the CD16 site of NK cell surface cells to enhance the stimulation of IL-15 and IL-2 to NK cells and the killing effect of ADCC to tumor cells, so that the NK cells are induced to be activated, and the NK cells with higher amplification efficiency and purity are obtained. The technology does not use magnetic beads to sort cells, does not use a trophoblast cell activation method, and has the advantages of simple operation, quick response, low preparation cost and high safety. Can efficiently expand NK cells, and the cells expand 148 times within 14 days (shown in figure 2). No CD16 antibody stimulated proliferation by less than 100-fold. Therefore, the NK cells obtained by the method have high purity and high clinical value.
The embodiments of the present invention have been described in detail with reference to the drawings, but the present invention is not limited thereto, and various changes can be made within the knowledge of those skilled in the art without departing from the gist of the present invention.
Claims (5)
- A culture method for in vitro expansion of NK cells by combining CD16 antibody and cytokine, which is characterized by comprising the following steps:s1, separating mononuclear cells from peripheral blood;s2, inoculating peripheral blood mononuclear cells into a precoated RetroNectin and mouse anti-human CD16 cell culture bottle, and adding a culture medium containing IL-2, IL-15, IL-21 and autologous plasma;s3, continuously culturing for 14-17 days to obtain high-purity high-activity NK cells.
- 2. The method for culturing the NK cells expanded in vitro by the CD16 antibody and the cytokine according to claim 1, wherein the coating solution is prepared before culturing.
- 3. The method for culturing the NK cells expanded in vitro by the CD16 antibody and the cytokine according to claim 1, wherein the coating solution comprises 10ml PBS, 35ug Retrocin and 35ug CD16 antibody, and the mixture is prepared.
- 4. The culture method for the in vitro expansion of NK cells by the combination of CD16 antibody and cytokine according to claim 1, comprising the following steps:A. coating: adding the coating solution into a culture bottle, uniformly spreading and flatly placing, and keeping out of the sun overnight at the temperature of 4 ℃;B. blood collection: collecting 15ml of peripheral blood, and adding the peripheral blood into a first centrifugal tube for later use;C. separating lymphocyte separation liquid: adding PBS with the same volume as the PBS to 30ml into a centrifuge tube, uniformly mixing, transferring to a centrifuge tube II added with 15ml of lymph separation liquid in advance, centrifuging at 1800rpm/800g at room temperature for 20min, and setting the speed of acceleration and deceleration as 0;D. washing PBMC: sucking out the white PBMC layer after centrifugation by using a suction tube, adding 18-22ml of PBS into the centrifuge tube III for cleaning, centrifuging for 6min at 2000rpm, and discarding the supernatant; washing with 20ml PBS again, centrifuging at 1800rpm for 6min, and discarding the supernatant; resuspending with culture medium, mixing, sampling, counting with typandlue staining, centrifuging at 1800rpm for 6min, and discarding the supernatant;E. preparing a cell suspension: suspending the cells with 40ml of culture medium, precipitating and mixing;F. inoculating cells: adding 40m of the cell suspension into a culture bottle, adding IL-15 with the final concentration of 30ng/ml, IL-21 with the final concentration of 100ng/ml, autologous plasma with the final concentration of 5% and IL-2 with the final concentration of 6000U/ml, and placing the inoculated culture bottle into a carbon dioxide incubator for culture;G. flasks were grown for 4, 6, 8, 11 and 14 days during which time they were examined and cells were recovered on day 17.
- 5. The culture method for the in vitro expansion of NK cells by the combination of CD16 antibody and cytokine according to claim 1, characterized in that the culture conditions of the carbon dioxide incubator are as follows: at a temperature of 37 ℃ and CO 2 The concentration was 5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210794041.7A CN115074326A (en) | 2022-07-07 | 2022-07-07 | Culture method for in-vitro amplification of NK cells by combining CD16 antibody with cytokine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210794041.7A CN115074326A (en) | 2022-07-07 | 2022-07-07 | Culture method for in-vitro amplification of NK cells by combining CD16 antibody with cytokine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115074326A true CN115074326A (en) | 2022-09-20 |
Family
ID=83258685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210794041.7A Pending CN115074326A (en) | 2022-07-07 | 2022-07-07 | Culture method for in-vitro amplification of NK cells by combining CD16 antibody with cytokine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115074326A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115651903A (en) * | 2022-11-14 | 2023-01-31 | 四川新生命干细胞科技股份有限公司 | High-lethality immune cell population and culture method, reagent composition and application thereof |
| CN118325833A (en) * | 2023-01-10 | 2024-07-12 | 上海恩凯细胞技术有限公司 | Method for in vitro induction amplification of high-purity high-cytotoxic activity NK cells |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107326008A (en) * | 2017-08-09 | 2017-11-07 | 上海莱馥医疗科技有限公司 | A kind of method of high-purity amplifying natural killer cell efficient from peripheral blood |
| CN108642012A (en) * | 2018-07-03 | 2018-10-12 | 广东龙帆生物科技有限公司 | A kind of method of derived from peripheral blood NK cell high-efficients amplification |
| CN109294985A (en) * | 2018-10-25 | 2019-02-01 | 江苏普瑞康生物医药科技有限公司 | A method of culture medium system and NK cell expansion ex vivo for NK cell expansion ex vivo |
| CN110643573A (en) * | 2019-10-23 | 2020-01-03 | 武汉济源高科技有限公司 | Method for culturing chained NK cells |
| CN111690610A (en) * | 2020-07-22 | 2020-09-22 | 暨赛再生医学科技有限公司 | Method for preparing natural killer NK (natural killer) cells through efficient induction culture |
| US20210355445A1 (en) * | 2019-05-15 | 2021-11-18 | Forevernk Inc. | Kit containing medium for culturing natural killer cells and method of effectively culturing natural killer cells using the same |
| CN114196630A (en) * | 2022-01-17 | 2022-03-18 | 顾加明 | NK cell culture medium and NK cell culture method |
-
2022
- 2022-07-07 CN CN202210794041.7A patent/CN115074326A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107326008A (en) * | 2017-08-09 | 2017-11-07 | 上海莱馥医疗科技有限公司 | A kind of method of high-purity amplifying natural killer cell efficient from peripheral blood |
| CN108642012A (en) * | 2018-07-03 | 2018-10-12 | 广东龙帆生物科技有限公司 | A kind of method of derived from peripheral blood NK cell high-efficients amplification |
| CN109294985A (en) * | 2018-10-25 | 2019-02-01 | 江苏普瑞康生物医药科技有限公司 | A method of culture medium system and NK cell expansion ex vivo for NK cell expansion ex vivo |
| US10450547B1 (en) * | 2018-10-25 | 2019-10-22 | Purecell Biomedical Technology Company Limited | Medium system and method for ex vivo expansion of NK cells |
| US20210355445A1 (en) * | 2019-05-15 | 2021-11-18 | Forevernk Inc. | Kit containing medium for culturing natural killer cells and method of effectively culturing natural killer cells using the same |
| CN110643573A (en) * | 2019-10-23 | 2020-01-03 | 武汉济源高科技有限公司 | Method for culturing chained NK cells |
| CN111690610A (en) * | 2020-07-22 | 2020-09-22 | 暨赛再生医学科技有限公司 | Method for preparing natural killer NK (natural killer) cells through efficient induction culture |
| CN114196630A (en) * | 2022-01-17 | 2022-03-18 | 顾加明 | NK cell culture medium and NK cell culture method |
Non-Patent Citations (6)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115651903A (en) * | 2022-11-14 | 2023-01-31 | 四川新生命干细胞科技股份有限公司 | High-lethality immune cell population and culture method, reagent composition and application thereof |
| CN118325833A (en) * | 2023-01-10 | 2024-07-12 | 上海恩凯细胞技术有限公司 | Method for in vitro induction amplification of high-purity high-cytotoxic activity NK cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107083363B (en) | Peripheral blood NK cell in-vitro efficient amplification method | |
| CN110747166B (en) | In-vitro amplification culture method for peripheral blood T cells | |
| CN115074326A (en) | Culture method for in-vitro amplification of NK cells by combining CD16 antibody with cytokine | |
| CN111440773B (en) | Optimized culture method for T cell in-vitro chimeric antigen receptor modification and amplification | |
| CN112391344B (en) | In-vitro amplification and culture method for non-coated NK cells | |
| CN113699106A (en) | Separation and amplification method of killer cells induced by cytokines | |
| CN111944754A (en) | Natural killer cell culture method | |
| CN114196630A (en) | NK cell culture medium and NK cell culture method | |
| CN117343902A (en) | In-vitro amplification culture method for high-purity NK cells | |
| CN112680415A (en) | NK culture medium and amplification culture method thereof | |
| CN113293132A (en) | NK cell in-vitro amplification system and culture method | |
| CN113564117B (en) | In-vitro expansion optimization method for cryopreserved umbilical cord blood-derived regulatory T cells | |
| CN114075546A (en) | NK cell amplification composition and in-vitro amplification culture method | |
| CN116376828A (en) | Method for inducing CD4+ T cells to generate Treg cells and application | |
| WO2022194118A1 (en) | Perfusion culture method for car-t cells | |
| CN110499291B (en) | Method for preparing chimeric antigen receptor T cells by serum-free culture | |
| CN115044552A (en) | In-vitro culture method and kit for natural killer cells | |
| CN113249321A (en) | Peripheral blood NK cell culture method | |
| CN111548994A (en) | Cell culture medium and method for culturing NK cells by using same | |
| CN115074325A (en) | Herceptin combined 4-1BBL in-vitro amplification NK method | |
| CN108165530B (en) | Separated and purified mouse tumor tissue infiltration CD4+CD25+Method for regulatory T cells | |
| CN112725273A (en) | NK cell and preparation method and application thereof | |
| CN114807031A (en) | Construction method of human peripheral blood immune cell bank and stem cell bank | |
| CN113755436A (en) | In-vitro NK cell amplification method and NK cell | |
| CN113564115A (en) | High-amplification DC-CIK cell and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |